In the first clinical study of a vaginal ring that releases the antiretroviral drug dapivirine as well as a contraceptive hormone, there were no safety concerns and the ring was well-tolerated, researchers from the National Institutes of Health-funded Microbicide Trials Network (MTN) reported today at the HIV Research for Prevention conference (HIVR4P 2018) in Madrid.
All news from R&D
The Walter Reed Army Institute of Research (WRAIR) administered the first vaccine in Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine candidate in healthy adult volunteers.
Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, you have highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and early childhood clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.
The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL. It was hoped this research, carried out by UCL Great Ormond Street Institute of Child Health (ICH), in collaboration with Great Ormond Street Hospital (GOSH) and the Francis Crick Institute, could pave the way for clinical trials of lab-grown food pipes for children with congenital and acquired gut conditions.
Researchers at the US Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) and SUNY Upstate Medical University in Syracuse, NY, have been granted a grant to advance an experimental heroin vaccine through Phase I / IIa clinical trials to assess both its safety and its effectiveness against a morphine challenge.
A research group presented a novel biosensor which can produce diverse, high-level microbial cell factories. The biosensor monitors the concentration of products and even intermediates when new strains are being developed. This strategy provides a new platform for manufacturing diverse natural products from renewable resources. The team succeeded in creating four natural products of high-level pharmaceutical importance with this strategy.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4% for 53 patients evaluable for response, with median duration of response of 24.6 months.
A substantial proportion of pharmaceutical industry payments to authors of oncology clinical trials published in major scientific journals are not disclosed new research shows. The publications focused on clinical trials that tested new cancer drugs. The new findings will be published as a research letter in the journal JAMA Oncology.
A group of researchers affiliated to the University of São Paulo (USP) – campus Ribeirão Preto, Brazil, used big data tools such as data mining and network analysis to develop a method to help scientists and companies identify technological routes, trends and partnerships in any knowledge area. For this purpose, it collected information from patent databases around the world.
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.
The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear. At the 2018 European Society of Cardiology meeting, J. Michael Gaziano presented findings from ARRIVE, a randomized, controlled clinical trial of the use of daily aspirin to prevent a first cardiovascular event among more than 12,500 participants considered to be at moderate cardiovascular risk. The team's findings are detailed in a paper published simultaneously in The Lancet.
A self-healing membrane that acts as a reverse filter, blocking small particles and letting large ones through, is the 'straight out of science fiction' say mechanical engineers.